Related references
Note: Only part of the references are listed.High subclonal fraction of 17p deletion is associated with poor prognosis in multiple myeloma
Anjan Thakurta et al.
BLOOD (2019)
Lenalidomide maintenance versus observation for patients with newly diagnosed multiple myeloma (Myeloma XI): a multicentre, open-label, randomised, phase 3 trial
Graham H. Jackson et al.
LANCET ONCOLOGY (2019)
Response-adapted intensification with cyclophosphamide, bortezomib, and dexamethasone versus no intensification in patients with newly diagnosed multiple myeloma (Myeloma XI): a multicentre, open-label, randomised, phase 3 trial
Graham H. Jackson et al.
LANCET HAEMATOLOGY (2019)
Prediction of outcome in newly diagnosed myeloma: a meta-analysis of the molecular profiles of 1905 trial patients
V. Shah et al.
LEUKEMIA (2018)
The presence of large focal lesions is a strong independent prognostic factor in multiple myeloma
Leo Rasche et al.
BLOOD (2018)
Subclonal TP53 copy number is associated with prognosis in multiple myeloma
Vallari Shah et al.
BLOOD (2018)
Whole-Body Imaging in Multiple Myeloma
Christina Messiou et al.
MAGNETIC RESONANCE IMAGING CLINICS OF NORTH AMERICA (2018)
Lenalidomide, Bortezomib, and Dexamethasone with Transplantation for Myeloma
Michel Attal et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
New criteria for response assessment: role of minimal residual disease in multiple myeloma
Bruno Paiva et al.
BLOOD (2015)
Share Paper
